品牌分类
品牌咨询
联系方式
公司地址
苏州工业园区生物纳米园A4#216
联系电话
4000-520-616 / 18915418616
传真号码
0512-67156496
电子邮箱
info@ebiomall.com
公司网址
https://www.ebiomall.com
商品描述
Details
Xcess新型高效神经保护分子P7C32014年10月13日03:55 | 新闻印刷版刚刚在上个月的Cell中发表，最近关于神经保护小分子P7C3的 MOA研究具有广泛的体外和体内活性，为研究共享其他常见组织的神经系统疾病，损伤，发育和退行性疾病提供了新的令人兴奋的机会机制。 P7C3 是直接从体内神经发生筛选中鉴定出的无毒，稳定且可口服生物利用的合成小分子。它可以保护齿状回中的新生神经元，并刺激新神经元的生长。它还可以增强老年大鼠的学习和记忆能力。在爆炸介导的创伤性脑损伤（TBI）的啮齿动物模型中，P7C3还可以在损伤后，在神经元细胞死亡发生之前保持轴突的完整性。MOA研究表明P7C3可以结合烟酰胺磷酸核糖基转移酶（NAMPT），这是一种将烟酰胺转化为烟酰胺腺嘌呤二核苷酸（NAD）的限速酶。将活性P7C3化学物质施用至用阿霉素处理的细胞（诱导NAD耗竭），可导致细胞内NAD水平反弹，并免受阿霉素介导的毒性的影响。 如何订购： Xcess Biosciences是一家领先的试剂和服务公司，提供10 mM DMSO溶液和以克计的固体形式的化合物。请访问我们的网站以获取订单信息和其他创新产品。特别是Xcess Biosciences继续向我们的表观遗传调节剂工具箱 （现在我们提供72种独特的化合物）和 泛素调节剂工具箱 （现在我们提供15种独特的化合物）中添加了更多新颖的小分子化学探针 。
Product Information
| Molecular Weight: | 411.54 |
| Formula: | C23H23N5O2 |
| Purity: | >98% |
| CAS#: | 354813-19-7 |
| Solubility: | DMSO: ≥ 46 mg/mL |
| Chemical Name: | N-(1-((cyanomethyl)carbamoyl)cyclohexyl)-4-(4-propylpiperazin-1-yl)benzamide |
| Storage: | Powder -20oC 3 years 4oC 2 yearsIn solvent -80oC 6 months-20oC 1 month |
Biological Activity:
Balicatib(AAE-581) is a potent and selective inhibitor of cathepsin K; 10-100 fold more potent in cell-based enzyme occupancy assays than against cathepsin B, L, and S. IC50 value: Target: cathepsin K The cathepsin K inhibitor AAE-581 (balicatib) as the most advanced of them passed Phase II clinical trials in 2005. Eighty adult female Macaca fascicularis underwent bilateral ovariectomies and were dosed twice daily by oral gavage with balicatib at 0, 3, 10, and 50 mg/kg for 18 months (groups O, L, M, H, respectively). Approximately 1 month after treatment initiation, the 50 mg/kg dose was decreased to 30 mg/kg. Twenty animals underwent sham-ovariectomies (group S). Bone mass was measured at 3-6 month intervals. At 18 months, vertebra and femur were collected for histomorphometry.
Reference:
[1]. Falgueyret JP, et al. Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J Med Chem. 2005 Dec 1;48(24):7535-43.
[2]. Vasiljeva O, et al. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des. 2007;13(4):387-403.
[3]. Jerome C, et al. Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys. Osteoporos Int. 2011 Dec;22(12):3001-11.
